Glucagon-like peptide-2 is a gut hormone that grows and repairs the intestine. Learn how it differs from GLP-1, what teduglutide treats, and its risks.
Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid hormone made by L-cells in the small intestine and colon that stimulates growth and repair of the intestinal lining. It is not a weight-loss hormone, and no GLP-2 product is FDA-approved for obesity. The only GLP-2 medicine approved for human use in the United States is teduglutide, an injectable drug for short bowel syndrome.
What Is Glucagon-Like Peptide-2?
Glucagon-like peptide-2 belongs to the same family as glucagon and glucagon-like peptide-1, because all three are carved out of one precursor protein encoded by the GCG gene. The body processes that precursor differently in the pancreas than in the gut, which is why a single gene produces hormones with very different jobs.
GLP-2 is released into the bloodstream after a meal, especially when the meal contains fat or carbohydrate. Its natural half-life is only about 7 minutes because the enzyme DPP-4 degrades it quickly, so the hormone works in short pulses rather than one long signal.
What Does Glucagon-Like Peptide-2 Do in the Body?
GLP-2 binds to the GLP-2 receptor, a G-protein-coupled receptor found on enteric neurons, enteroendocrine cells, and subepithelial myofibroblasts in the gut wall. Activation triggers growth and repair signals that make the intestine larger and more efficient at absorbing nutrients. The main effects include:
- Stimulating crypt cell proliferation, which lengthens intestinal villi and deepens the crypts.
- Reducing enterocyte apoptosis so absorptive cells live longer.
- Increasing blood flow through the mesenteric vessels that supply the intestines.
- Strengthening the intestinal barrier and lowering permeability.
- Slowing gastric emptying and reducing gastric acid secretion.
- Improving uptake of fluids, electrolytes, and nutrients.
Researchers describe these combined actions as trophic, meaning they build tissue. Scientists study glucagon-like peptide 2 mainly in people with a shortened or damaged intestine, not in people seeking weight loss.
Glucagon-Like Peptide-2 vs. GLP-1
Most people run into GLP-2 while reading about a different hormone. Search interest in glucagon like peptide 2 has grown mostly as a side effect of GLP-1's popularity, and it is easy to assume every gut peptide suppresses appetite. They do not.
GLP-1 is the hormone behind the glucagon-like peptide-1 receptor agonist class, which includes glucagon-like peptide-1 drugs such as semaglutide, liraglutide, and dulaglutide. Those medicines slow digestion, increase fullness, and lower blood glucose. GLP-1 also drives glucose-dependent insulin release, which is the basis of most glucagon like peptide 1 benefits studied in type 2 diabetes.
| Feature | Glucagon-Like Peptide-2 | Glucagon-Like Peptide-1 |
|---|---|---|
| Primary role | Intestinal growth and repair | Appetite, digestion, and blood sugar |
| Receptor | GLP-2 receptor | GLP-1 receptor |
| Natural half-life | About 7 minutes | About 1 to 2 minutes |
| Main metabolic effect | Increased nutrient absorption | Reduced appetite and lower glucose |
| Approved drugs | Teduglutide | Semaglutide, liraglutide, dulaglutide, exenatide |
| Typical weight effect | Neutral to weight gain | Weight loss |
GLP-2 Medications: Teduglutide and Short Bowel Syndrome
Teduglutide (brand name Gattex in the US) is a recombinant GLP-2 analog modified to resist DPP-4, which extends its half-life to roughly 2 to 3 hours after a subcutaneous injection. The FDA approved it in 2012 for adults with short bowel syndrome who depend on intravenous parenteral nutrition, and it is also approved for some pediatric patients.
In clinical trials, teduglutide helped a portion of patients reduce or eliminate their need for parenteral support. That matters for people who have lost a large share of their small intestine to surgery, Crohn's disease, or trauma, because the remaining gut often cannot absorb enough nutrition on its own.
Two other GLP-2 analogs, glepaglutide and apraglutide, have been tested in late-stage trials. Both aim for longer dosing intervals or a wider range of patients.
| GLP-2 Analog | Status | Notes |
|---|---|---|
| Teduglutide (Gattex) | FDA-approved | Daily injection for short bowel syndrome |
| Glepaglutide | Investigational | Studied in short bowel syndrome with less frequent dosing |
| Apraglutide | Investigational | Studied in short bowel syndrome and other absorption disorders |
Side Effects and Safety Concerns
Because GLP-2 pushes cells to grow, its safety profile deserves real attention. The prescribing information for teduglutide carries warnings about intestinal neoplasia, intestinal obstruction, biliary and pancreatic disease, and fluid overload.
- Common side effects: abdominal pain, nausea, injection-site reactions, headache, and peripheral swelling.
- Serious risks: bowel obstruction, gallbladder and pancreatic problems, and fluid retention that can worsen heart failure.
- Monitoring: because animal studies showed colon polyps and tumors, patients are usually followed with colonoscopy before and during treatment.
GLP-2 is not sold as a dietary supplement in the United States, and no over-the-counter peptide product has been shown to reproduce its effects. Anyone considering peptide therapy should review risks, monitoring, and alternatives with a healthcare professional first.
Does Glucagon-Like Peptide-2 Cause Weight Loss?
No. Glucagon-like peptide-2 does not produce the strong appetite suppression seen with GLP-1, and clinical trials of teduglutide have not shown meaningful weight loss. Some patients do gain weight once their intestines absorb more calories than before treatment.
People searching for glucagon-like peptide weight loss results are almost always looking for GLP-1 therapies, not GLP-2. If appetite control is the goal, the evidence points to GLP-1-based medication prescribed and monitored by a clinician.
GLP-2 has one clear clinical role: helping an intestine that cannot absorb enough on its own. It is not a wellness peptide, and it is not interchangeable with GLP-1 drugs. Patients with short bowel syndrome or another malabsorption condition should ask a gastroenterologist whether GLP-2 therapy is appropriate and what monitoring it requires.
Frequently Asked Questions
Is glucagon-like peptide-2 the same as GLP-1?
No. GLP-2 and GLP-1 are made from the same gene, but they bind different receptors and do different jobs. GLP-1 regulates appetite, digestion, and blood sugar, while GLP-2 drives intestinal growth and nutrient absorption.
Is GLP-2 available as a supplement?
No. GLP-2 is not sold as a dietary supplement in the United States, and no oral peptide product has been shown to reproduce its effects. The only approved GLP-2 therapy is teduglutide, which is a prescription injection.
What is teduglutide used for?
Teduglutide treats short bowel syndrome in adults and in some pediatric patients who depend on parenteral nutrition. It can help patients reduce or stop intravenous support, but it carries serious risks, including intestinal obstruction, biliary and pancreatic problems, and fluid overload.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.